Prevention and treatment of nonalcoholic fatty liver disease by traditional Chinese medicine

Sui, Xiaodan; Deng, Hou-Bo; Liu, Tiejun

doi:10.11569/wcjd.v21.i18.1708

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current Chinese guidelines, lifestyle interventions and weight management are the first-line therapies for NAFLD, which are consistent with the globally followed guidelines or consensus. 59,60 Angiotensin-receptor blockers, statins, omega-3 polyunsaturated fatty acids, metformin and pioglitazone can be used to treat specific metabolic disorders in patients without either liver failure or decompensated cirrhosis. However, none of these nor any hepatoprotective drugs has been licensed with an indication for the treatment of NAFLD or NASH.…”

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

“…Bariatric surgery has been proven to show histological improvement in NASH, but it requires more evidence to become a recommended therapy for this entity. 59,61 With the increasing prevalence of NAFLD/NASH, the number of clinical trials on various therapies has surged in China in recent years.…”

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

“…The peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone has been considered as an option for patients with NASH and T2DM to improve their hepatic fibrosis score and hepatic fat content as recommended by the Chinese Society of Hepatology guidelines. 59 Chiglitazar is an innovative pan-PPAR (α, δ and γ) agonist developed in China. Since October 2021, chiglitazar has been approved by the Center for Drug Evaluation for the treatment of patients with T2DM due to its relatively good efficacy and safety profiles.…”

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

See 2 more Smart Citations

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Liu

Hong

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the http://www.clinicaltrials.gov and http://www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China. Results The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH. Conclusions NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

show abstract

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

See 1 more Smart Citation